2025.12.25
Joint Industry Statement Calls for Reform of Japan’s FY2026 NHI Drug Pricing and Cost-Effectiveness Assessment System
Introduction to Policy DiscussionAccording to a joint statement (Joint Statement on Need for FY2026 NHI Drug P […]
2025.06.25
JPMA Responds to the 2025 Honebuto Policy: Emphasizing Reform of Cost-Effectiveness Evaluation and Pricing Framework
Introduction to Japan’s 2025 Honebuto Policy According to a news article (製薬協 費用対効果評価「現行の枠組みにとらわれない新たな制度 […]
2025.05.29
Key Amendments to the PMD Act — Strengthening Conditional Approval and Post-Market Safety
Introduction to Legislative ProgressAccording to news (薬機法等改正法案 参院厚労委で賛成多数で可決 15項目の附帯決議採択 14日にも成立へ | ニュース | ミク […]